Immunocore to present at upcoming investor conferences
(OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 1 September 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate at the following conferences in September.
Cantor Global Healthcare Conference 2026
Fireside Chat: Thursday, September 10, 2026, at 2:45 p.m. EDT
Morgan Stanley 24th Annual Global Healthcare Conference
Fireside Chat: Monday, September 14, 2026, at 2:35 p.m. EDT
Baird 2026 Global Healthcare Conference
Fireside Chat: Tuesday, September 15, 2026, at 12:15 p.m. EDT
H.C. Wainwright 28th Annual Global Investment Conference
1x1 and small group meetings: Wednesday, September 16, 2026
The presentations will be webcast live and can be accessed by visiting ‘Events & Presentations’, under ‘Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the event, a replay of the presentation will be made available for a limited time.
About Immunocore
Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune diseases and infectious diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including clinical and pre-clinical programs in oncology, infectious diseases, and autoimmune diseases. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.
Contact Information
Immunocore
Sébastien Desprez, Vice President Communications
T: +44 (0) 7458030732
E: [email protected]
Follow on LinkedIn: @Immunocore
Ryan Baker, Vice President of Investor Relations
T: +1 (215) 384-4781
E: [email protected]